UBS Group’s Xilio Therapeutics XLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $163K | Buy |
239,969
+76,868
| +47% | +$52.3K | ﹤0.01% | 5610 |
|
|
2025
Q1 | $118K | Sell |
163,101
-86,300
| -35% | -$62.5K | ﹤0.01% | 5654 |
|
|
2024
Q4 | $238K | Buy |
249,401
+233,668
| +1,485% | +$223K | ﹤0.01% | 5155 |
|
|
2024
Q3 | $12.4K | Buy |
15,733
+15,532
| +7,727% | +$12.2K | ﹤0.01% | 6427 |
|
|
2024
Q2 | $191 | Hold |
201
| – | – | ﹤0.01% | 7920 |
|
|
2024
Q1 | $217 | Hold |
201
| – | – | ﹤0.01% | 7553 |
|
|
2023
Q4 | $111 | Hold |
201
| – | – | ﹤0.01% | 7697 |
|
|
2023
Q3 | $424 | Hold |
201
| – | – | ﹤0.01% | 7356 |
|
|
2023
Q2 | $527 | Hold |
201
| – | – | ﹤0.01% | 7104 |
|
|
2023
Q1 | $637 | Hold |
201
| – | – | ﹤0.01% | 7845 |
|
|
2022
Q4 | $541 | Hold |
201
| – | – | ﹤0.01% | 8939 |
|
|
2022
Q3 | $1K | Sell |
201
-2,613
| -93% | -$13K | ﹤0.01% | 8946 |
|
|
2022
Q2 | $9K | Buy |
2,814
+1,850
| +192% | +$5.92K | ﹤0.01% | 7140 |
|
|
2022
Q1 | $7K | Sell |
964
-3,013
| -76% | -$21.9K | ﹤0.01% | 7794 |
|
|
2021
Q4 | $64K | Buy |
+3,977
| New | +$64K | ﹤0.01% | 5614 |
|